Manolis Dermitzakis | Innovation in drug discovery

We will explore the foundational principles of drug discovery, identifying areas in need of improvement and innovation. Additionally, we will delve into the role of emerging technologies like AI/ML and how they can contribute to advancing this field. Furthermore, we will examine how the entrepreneurial landscape is fostering innovation within both Big Pharma and small biotech companies.

Participants:
Manolis Dermitzakis: Vice President, Computational Biology, GSK

Emmanouil (Manolis) Dermitzakis is currently VP and head of Computational Biology at GSK. He previously was Professor of Genetics in the Department of Genetic Medicine and Development, University of Geneva Medical School, Director of the Health2030 Genome Center and Director of the Institute of Genetics and Genomics in Geneva. He previously served as Chairman of the National Council for Research, Technology and Innovation and advisor to the Prime Minister in Greece. He also served as president of the World Hellenic Biomedical Association (2014-2015). He obtained his B.Sc. (1995) and M.Sc. (1997) from the University of Crete (Greece) and his PhD in 2001 from the Pennsylvania State University in the USA. His post-doctoral work was at the University of Geneva Medical School. He previously was a Senior Investigator at the Wellcome Sanger Institute in Cambridge. He was
elected EMBO member in 2014, recipient of the 2017 Bodossakis science award and
the American Society of Human Genetics achievement award, and has been named
Highly Cited Researcher by ISI every year since 2014.